Infinity Reports Encouraging Phase 1 IPI-145 Data at ASH
December 08, 2013 at 10:35 AM EST
Infinity Pharmaceuticals (NASDAQ: INFI ) today announced updated data from a Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
